While the pioneering work on cancer immunotherapy by Allison JP and Honjo T earned them the 2018 Nobel Prize in Physiology or Medicine, particularly for their advancements with immune checkpoint inhibitors like anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) and anti-Programmed Death-1 (PD-1) antibodies, the outcomes of such treatments in PDAC have been less promising [45]. Here, CTLA4 is linked to cancer.